Cargando…

Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin

BACKGROUND: Teicoplanin is a glycopeptide antibiotic used clinically in Europe and in Japan for the treatment of multi-resistant Gram-positive infections. It is produced by fermenting Actinoplanes teichomyceticus. The pharmaceutically active principle is teicoplanin A(2), a complex of compounds desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Taurino, Carlo, Frattini, Luca, Marcone, Giorgia Letizia, Gastaldo, Luciano, Marinelli, Flavia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250949/
https://www.ncbi.nlm.nih.gov/pubmed/22008254
http://dx.doi.org/10.1186/1475-2859-10-82
_version_ 1782220506691272704
author Taurino, Carlo
Frattini, Luca
Marcone, Giorgia Letizia
Gastaldo, Luciano
Marinelli, Flavia
author_facet Taurino, Carlo
Frattini, Luca
Marcone, Giorgia Letizia
Gastaldo, Luciano
Marinelli, Flavia
author_sort Taurino, Carlo
collection PubMed
description BACKGROUND: Teicoplanin is a glycopeptide antibiotic used clinically in Europe and in Japan for the treatment of multi-resistant Gram-positive infections. It is produced by fermenting Actinoplanes teichomyceticus. The pharmaceutically active principle is teicoplanin A(2), a complex of compounds designated T-A(2-1)-A(2-5 )differing in the length and branching of the fatty acid moiety linked to the glucosamine residue on the heptapeptide scaffold. According to European and Japanese Pharmacopoeia, components of the drug must be reproduced in fixed amounts to be authorized for clinical use. RESULTS: We report our studies on optimizing the fermentation process to produce teicoplanin A(2 )in A. teichomyceticus ATCC 31121. Robustness of the process was assessed on scales from a miniaturized deep-well microtiter system to flasks and 3-L bioreactor fermenters. The production of individual factors T-A(2-1)-A(2-5 )was modulated by adding suitable precursors to the cultivation medium. Specific production of T-A(2-1), characterized by a linear C10:1 acyl moiety, is enhanced by adding methyl linoleate, trilinoleate, and crude oils such as corn and cottonseed oils. Accumulation of T-A(2-3), characterized by a linear C10:0 acyl chain, is stimulated by adding methyl oleate, trioleate, and oils such as olive and lard oils. Percentages of T-A(2-2), T-A(2-4), and, T-A(2-5 )bearing the iso-C10:0, anteiso-C11:0, and iso-C11:0 acyl moieties, respectively, are significantly increased by adding precursor amino acids L-valine, L-isoleucine, and L-leucine. Along with the stimulatory effect on specific complex components, fatty acid esters, oils, and amino acids (with the exception of L-valine) inhibit total antibiotic productivity overall. By adding industrial oils to medium containing L-valine the total production is comparable, giving unusual complex compositions. CONCLUSIONS: Since the cost and the quality of teicoplanin production depend mainly on the fermentation process, we developed a robust and scalable fermentation process by using an industrial medium in which a complex composition can be modulated by the combined addition of suitable precursors. This work was performed in the wild-type strain ATCC 31121, which has a clear genetic background. This is important for starting a rational improvement program and also helps to better control teicoplanin production during process and strain development.
format Online
Article
Text
id pubmed-3250949
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32509492012-01-06 Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin Taurino, Carlo Frattini, Luca Marcone, Giorgia Letizia Gastaldo, Luciano Marinelli, Flavia Microb Cell Fact Research BACKGROUND: Teicoplanin is a glycopeptide antibiotic used clinically in Europe and in Japan for the treatment of multi-resistant Gram-positive infections. It is produced by fermenting Actinoplanes teichomyceticus. The pharmaceutically active principle is teicoplanin A(2), a complex of compounds designated T-A(2-1)-A(2-5 )differing in the length and branching of the fatty acid moiety linked to the glucosamine residue on the heptapeptide scaffold. According to European and Japanese Pharmacopoeia, components of the drug must be reproduced in fixed amounts to be authorized for clinical use. RESULTS: We report our studies on optimizing the fermentation process to produce teicoplanin A(2 )in A. teichomyceticus ATCC 31121. Robustness of the process was assessed on scales from a miniaturized deep-well microtiter system to flasks and 3-L bioreactor fermenters. The production of individual factors T-A(2-1)-A(2-5 )was modulated by adding suitable precursors to the cultivation medium. Specific production of T-A(2-1), characterized by a linear C10:1 acyl moiety, is enhanced by adding methyl linoleate, trilinoleate, and crude oils such as corn and cottonseed oils. Accumulation of T-A(2-3), characterized by a linear C10:0 acyl chain, is stimulated by adding methyl oleate, trioleate, and oils such as olive and lard oils. Percentages of T-A(2-2), T-A(2-4), and, T-A(2-5 )bearing the iso-C10:0, anteiso-C11:0, and iso-C11:0 acyl moieties, respectively, are significantly increased by adding precursor amino acids L-valine, L-isoleucine, and L-leucine. Along with the stimulatory effect on specific complex components, fatty acid esters, oils, and amino acids (with the exception of L-valine) inhibit total antibiotic productivity overall. By adding industrial oils to medium containing L-valine the total production is comparable, giving unusual complex compositions. CONCLUSIONS: Since the cost and the quality of teicoplanin production depend mainly on the fermentation process, we developed a robust and scalable fermentation process by using an industrial medium in which a complex composition can be modulated by the combined addition of suitable precursors. This work was performed in the wild-type strain ATCC 31121, which has a clear genetic background. This is important for starting a rational improvement program and also helps to better control teicoplanin production during process and strain development. BioMed Central 2011-10-18 /pmc/articles/PMC3250949/ /pubmed/22008254 http://dx.doi.org/10.1186/1475-2859-10-82 Text en Copyright ©2011 Taurino et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Taurino, Carlo
Frattini, Luca
Marcone, Giorgia Letizia
Gastaldo, Luciano
Marinelli, Flavia
Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin
title Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin
title_full Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin
title_fullStr Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin
title_full_unstemmed Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin
title_short Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin
title_sort actinoplanes teichomyceticus atcc 31121 as a cell factory for producing teicoplanin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250949/
https://www.ncbi.nlm.nih.gov/pubmed/22008254
http://dx.doi.org/10.1186/1475-2859-10-82
work_keys_str_mv AT taurinocarlo actinoplanesteichomyceticusatcc31121asacellfactoryforproducingteicoplanin
AT frattiniluca actinoplanesteichomyceticusatcc31121asacellfactoryforproducingteicoplanin
AT marconegiorgialetizia actinoplanesteichomyceticusatcc31121asacellfactoryforproducingteicoplanin
AT gastaldoluciano actinoplanesteichomyceticusatcc31121asacellfactoryforproducingteicoplanin
AT marinelliflavia actinoplanesteichomyceticusatcc31121asacellfactoryforproducingteicoplanin